In mammalian RNA polymerase I transcription, SL1, an assembly of TBP and associated factors (TAFs), is essential for preinitiation complex formation at ribosomal RNA gene promoters in vitro. We provide evidence for a novel component of SL1, TAF I 41 (MGC5306), which functions in Pol I transcription. TAF I 41 resides at the rDNA promoter in the nucleolus and co-purifies and coimmunoprecipitates with SL1. TAF I 41 immunodepletion from nuclear extracts dramatically reduces Pol I transcription; addition of SL1 restores the ability of these extracts to support Pol I transcription. In cells, siRNAmediated decreased expression of TAF I 41 leads to loss of SL1 from the rDNA promoter in vivo, with concomitant loss of Pol I from the rDNA and reduced synthesis of the pre-rRNA. Extracts from these cells support reduced levels of Pol I transcription; addition of SL1 to the extracts raises the level of Pol I transcription. These data suggest that TAF I 41 is integral to transcriptionally active SL1 and imply a role for SL1, including the TAF I 41 subunit, in Pol I recruitment and, therefore, preinitiation complex formation in vivo.
Introduction
Accurate initiation of transcription by the three eukaryotic RNA polymerases, with few exceptions, requires a complex of TBP (TATA-box-binding protein) and TBP-associated factors (TAFs), which perform distinct roles in mediating a specific interaction between the polymerases and their target promoters (Hernandez, 1993; Goodrich and Tjian, 1994; Hahn, 1998) . The complement of TAFs in each complex is distinct to each class (Pol I, II or III) of genes and their cognate promoters.
There are substantial similarities in Pol I transcription of rDNA genes between organisms as diverse as yeast and mammals (reviewed in: Hannan et al, 1998; Grummt, 1999; Reeder, 1999; Nomura, 2001; Moss and Stefanovsky, 2002; Grummt, 2003; Moss, 2004; Russell and Zomerdijk, 2005) . In mammalian Pol I transcription in vitro, TBP-TAF complex SL1 (selectivity factor 1), known as TIF-IB in mouse, is essential (Comai et al, 1992 Zomerdijk et al, 1994; Heix et al, 1997; Friedrich et al, 2005) and upstream binding factor UBF functions as an activator of transcription (Bell et al, 1988; Jantzen et al, 1990; Hisatake et al, 1991; O'Mahony and Rothblum, 1991; Jantzen et al, 1992; Kuhn and Grummt, 1992) . UBF can influence rRNA gene expression at multiple levels, functioning as an activator at promoter escape by Pol I in vitro , as a regulator (repressor) of elongation (Stefanovsky et al, 2006) and as an antirepressor (Kuhn and Grummt, 1992; Brou et al, 1993; Pelletier et al, 2000) in the context of chromatin, and has been implicated in largescale chromatin decondensation in vivo (Chen et al, 2004; Mais et al, 2005) .
The human SL1 complex of B300 kDa includes TBP and the three TAF I s TAF I 48, TAF I 63 and TAF I 110 (Comai et al, 1992 Zomerdijk et al, 1994) . SL1 from human and rodents can bind the promoter independently and direct specific initiation of transcription in the absence of UBF (Smith et al, 1990 (Smith et al, , 1993 Schnapp and Grummt, 1991; Friedrich et al, 2005) . Core promoter binding is mediated by the TAF I s in SL1 (Rudloff et al, 1994; Beckmann et al, 1995) . Another important role for the TAF I s in SL1 inferred from in vitro analyses is in the recruitment of a functional Pol I complex to the start site via its interaction with human RRN3 (murine TIF-IA), a component of initiationcompetent Pol Ib (Miller et al, 2001; Yuan et al, 2002; Friedrich et al, 2005) . Furthermore, at least two subunits of SL1 interact with UBF (Kwon and Green, 1994; Beckmann et al, 1995) , and these interactions prevent the otherwise rapid dissociation of UBF from the rDNA promoter (Friedrich et al, 2005) . Taken together, the in vitro data imply that SL1 drives or nucleates preinitiation complex (PIC) formation at the rDNA promoter, leading to productive initiation of transcription by Pol I. Reconstitution of transcription in vitro using recombinant SL1 comprised of the four previously characterized components has been difficult and inefficient, suggesting that additional components and/or specific modifications might be required to assemble a fully active SL1 (Heix et al, 1997) . Here, we describe our identification of a novel TAF component of SL1 (TAF I 41) and present evidence that TAF I 41 plays an important role in Pol I transcription. In the course of these studies, we also uncovered evidence to suggest that SL1, including the TAF I 41 subunit, is required for Pol I recruitment and, thus, PIC formation in Pol I transcription in vivo.
Results and discussion
Human nucleolar protein TAF I 41 co-purifies with the SL1 protein complex and activity Silver staining of TBP-antibody affinity purified SL1 revealed only four major protein bands corresponding to TBP, and TAF I s 48, 63 and 110 (Comai et al, 1992) . However, aminoacid sequence analyses of tryptic peptides derived from the TBP and TAF I 48 region of the gel ) revealed a peptide (KQMNVGEDLENEDFD) with no homology to any of the previously identified TAFs or TBP, matching amino-acid sequences within several human ESTs and encoded by a gene (JOSD3 (Josephine domain containing protein 3) or MGC5306; accession number NM_024116) located on human chromosome 11q21. Other peptide sequences with homology to the protein encoded by this gene (KAIFERFK and KLAGDSFIVSSEFPVRLSVY) were derived from the same region of the gel, mixed with peptide sequences from TAF I 48 (KTSANISALIK and KGPVTDDEEV, respectively), confirming the presence of this protein in TBPantibody affinity purified SL1. The encoded protein of 278 amino acids (Supplementary Figure S1 ) has a calculated molecular weight of 32 kDa, but an apparent molecular weight of B41 kDa. (Intriguingly, a faint band of B41 kDa is sometimes visible on protein gels following silver staining of TBP-antibody affinity purified SL1 (Supplementary Figure  S2A) .) This protein has been reported to interact in a yeast two-hybrid assay with DNA polymerase b and a possible function in base excision repair was therefore suggested (Wang et al, 2004) . We provide evidence that this protein is also an SL1-specific TBP-associated factor (TAF I ) involved in Pol I transcription and refer to it hereafter as TAF I 41.
TAF I 41 contains a basic stretch of amino acids including a putative NLS (83-108), a serine-rich region in the N-terminal quarter of TAF I 41 and two acidic regions (184-192 and 200-216) , and these features are conserved in a putative mouse homologue, mTAF I 41 (accession number: NM_029248), of 322 amino acids and a calculated molecular weight of 37 kDa (Supplementary Figure S1 ) (variants NM_026541 and NM_027261 of 288 and 290 amino acids, respectively, and calculated molecular weight 33 kDa, are truncated in the C-terminus). mTAF I 41 shows 56% identity and 63% similarity to human TAF I 41 in the first 278 amino acids (Supplementary Figure S1) .
To explore the association between TAF I 41 and human SL1 from cells, SL1 was extensively purified from HeLa nuclear extracts as described in Figure 1A and B. Fractions from salt-gradient elution of the POROS Heparin column were analysed for the presence of TAF I 41 by immunoblotting, using an antibody generated against three TAF I 41 peptides (TAF I 41-peptides antibody), and for the ability to support SL1-dependent rDNA promoter-specific transcription. TAF I 41 co-purified with TAF I 110 and TAF I 63 subunits of SL1 and with SL1 activity ( Figure 1B ; POROS Heparin). The desalted 0.7 M POROS Heparin fraction of SL1 was applied to an SPSepharose column, step-eluted and applied to a TBP-antibody affinity column, yielding extensively purified SL1 (Supplementary Figure S2A , shows a silver-stain gel of SL1 similarly purified by Heparin Agarose, SP-Sepharose and TBP-antibody affinity chromatography). TAF I 41 co-purified with SL1 eluted from the TBP antibody column ( Figure 1B , TBP-antibody affinity column, lane 5). The peptide-eluted SL1 was passed over a Mono S column. Significantly, this extensively purified SL1 preparation demonstrated TAF I 41 in the fractions that contained SL1 activity ( Figure 1B ; Mono S).
Immunoblotting with TAF I 41-peptides antibody demonstrated that TAF I 41 co-migrates with TBP at B40 kDa ( Figure 1C , compare lanes 4 and 5); separation was achieved in 2D gels owing to the difference in the pIs of these proteins ( Figure 1D ). The electrophoretic mobility of TAF I 41 shifted upon dephosphorylation (data not shown), indicating that Figure 1 Human nucleolar protein TAF I 41 co-purifies with TBP-antibody affinity-purified SL1 and is found at the rDNA promoter in human cells. (A) Human SL1 purification scheme. For analytical purification of SL1, HeLa cell nuclear extract was applied to POROS Heparin Agarose and SP-Sepharose columns, as previously described (Comai et al, 1992; Friedrich et al, 2005) , then salt gradient eluted from a POROS Heparin column. The SL1 fractions were pooled, desalted on G25 Sepharose, step-eluted from SP-Sepharose and applied to a TBP-antibody affinity column. SL1 complexes were eluted with an excess of TBP (3G3) peptide and this eluate was applied to a Mono S column, which was developed by a linear salt gradient (KCl at concentrations (M) as indicated). (B) TAF I 41 co-purifies with SL1 protein and activity from HeLa cell nuclear extracts. Fractions obtained by salt gradient elution from the POROS Heparin column (B) were analysed for SL1 protein by immunoblotting, with antibodies specific for SL1 subunits TAF I 110 and TAF I 63, and an antibody generated against three peptides of TAF I 41 (see Materials and methods). The bulk of TAF I 41 eluted with the other SL1 subunits at 0.7 M KCl (fractions 21 and 22). Fraction 22 supported specific SL1-dependent reconstituted Pol I transcription. The 0.7 M KCl fraction was desalted to 0.2 M KCl, passed over SP-Sepharose and a saltstep elution was performed. The bulk of SL1 including TAF I 41 eluted at 0.65 M KCl and supported specific SL1-dependent transcription. This SL1 fraction was loaded onto a TBP-antibody affinity column (input, lane 1), some of which flowed through (FT, lane 4). The column was washed at 0.5 and 1.0 M KCl (lanes 2 and 3). Bound proteins from the washed column were eluted with excess TBP-epitope peptide 3G3 (1 mg/ ml) (lane 5) and fractions were immunoblotted for SL1 with antibodies specific for TAF I 110 and TAF I 63, and the TAF I 41-peptides antibody. SL1 was concentrated and purified away from the 3G3-peptide on a Mono S column, developed with a linear salt gradient. The Mono-S purified SL1 fractions 19-25 (fractions 19, 21, 23 and 25 are shown in lanes 7-10) were pooled and tested for the ability to support SL1-dependent transcription with UBF and Pol I (lanes 1-3, arrowhead). TAF I 41 is a phosphoprotein. Collectively, these data provide evidence to suggest that TAF I 41 is a previously overlooked subunit of human SL1. The comigration of TAF I 41 with TBP may explain why it had remained elusive for more than 10 years following the initial identification of SL1 subunits Zomerdijk et al, 1994) . Consistent with a role for TAF I 41 as a component of SL1 in Pol I transcription, overexpressed EGFP-TAF I 41 accumulated in the nucleoli, the site of Pol I transcription, ( Figure 1E ) and chromatin immunoprecipitation (ChIP) assays detected TAF I 41 and TBP at the rDNA promoter in cells ( Figure 1F ).
TAF I 41 co-immunoprecipitates with SL1 from human cells
Co-precipitation of EGFP-TAF I 41 with the endogenous SL1 subunits TAF I 110, TAF I 63 and TBP ( Figure 2A ) was detected following immunoprecipitation, using GFP-specific antibodies, from human cells expressing EGFP-TAF I 41. In a similar experiment with Flag-tagged TAF I 41, we also demonstrated co-precipitation of TAF I 41 with the SL1-subunits ( Figure 2B , lane 7). Conversely, endogenous TAF I 41 co-precipitated with Flag-TAF I 63 following immunoprecipitation, using Flag-s pecific antibodies, from human cells expressing Flag-tagged TAF I 63 ( Figure 2B , lane 5).
Furthermore, intact and functional SL1 was immunoprecipitated, with Flag-specific antibodies, from human cells expressing Flag-TAF I 41; the (Flag-peptide-eluted) immunocomplexes were capable of directing SL1-dependent accurate transcription initiation in reactions reconstituted with Pol Ib and the rDNA promoter ( Figure 2C , lanes 6, 7 and 8). SL1-dependent transcription was also observed with Flag immunocomplexes from extracts of cells expressing Flag-TAF I 63, a previously established subunit of SL1 (the difference in transcription levels perhaps reflecting differences in the specific activities and/or yields of functional SL1 complexes incorporating Flag-TAF I 41 or Flag-TAF I 63). Moreover, SL1 activity was detectable in immunocomplexes precipitated with TBP-specific antibodies, eluted with TBP-epitope peptide, and then re-precipitated with TAF I 41-specific antibody but not with IgG antibodies ( Figure 2D , lanes 4 and 5, respectively). Therefore, TAF I 41 appears to be an integral component of at least some portion of transcriptionally active SL1 complexes.
SL1 components TAF I 48, TAF I 63 and TAF I 110 have previously been shown to interact with each other and with TBP in GST pull-down experiments and in binding assays with in vitro translated or baculovirus-Sf9 cell-expressed proteins . TAF I 41 interacts detectably with the other TAFs of SL1 and, weakly, with TBP and RRN3 in such assays and with TAF I 110 in Far Western analyses (see Supplementary Figure S3 ). Although it is not known whether such interactions occur in the context of the SL1 complex or indeed the PIC, such interactions would be consistent with TAF I 41 being a subunit of the stable multiprotein complex SL1, with a potential role in the assembly of productive Pol I PICs.
The majority of the transcriptionally active SL1 complexes contain TAF I 41
We next asked whether immunodepletion of TAF I 41 from nuclear extracts would deplete a significant amount of SL1 activity. A TAF I 41 antibody generated against amino acids 98-204 of TAF I 41 (antibody D) selectively immunoprecipitated SL1 subunits TAF I 110, TBP and TAF I 41 from HeLa nuclear extract ( Figure 3A , lane 2 compared to lane 4) and, therefore, partially immunodepleted these SL1 subunits from the extract (the partial immunodepletion of TAF I 41 and TBP is detectable 5) or pcDNA-Flag-TAF I 63 (lanes 9-11), were tested for SL1-dependent activity in a specific transcription assay with Pol I, UBF and the rDNA promoter. Controls are transcription in a HeLa nuclear extract (lane 1) and from a partially purified SL1 fraction (the 0.7 M fraction from the POROS-Heparin column, see A, B; lane 2) added to the reconstituted transcription assay. (D) Endogenous TAF I 41 coimmunoprecipitates with TBP-containing complexes from human cells and the TAF I 41-TBP-containing complexes support rDNA promoterspecific Pol I transcription. TBP-containing complexes immunoprecipitated from HeLa cell nuclear extracts using TBP-specific monoclonal antibody (3G3) beads were eluted from the beads using an excess of epitope peptide, then incubated with TAF I 41-peptides antibody in a second IP. The SL1-dependent transcription activity of the TBP-TAF I 41-containing complexes was determined in an in vitro transcription assay with Pol I and UBF (lane 4). In the control sample, IgG was used in the second immunoprecipitation reaction in place of the TAF I 41-peptides antibody (lane 5). The SL1 activity of the input Hela nuclear extracts is shown in lane 3. Lanes 1 and 2 contain control reconstituted transcription reactions with Pol I and UBF, with and without SL1, respectively.
in Figure 3A , lane 1 compared to lane 3). The TAF I 41 antibody D-depleted extract supported a reduced level of Pol I transcription ( Figure 3B , lane 1 compared to lane 3). Addition of SL1 to the TAF I 41 antibody D-depleted extract restored the ability of the extract to support Pol I transcription ( Figure 3B , lane 2). These results suggest that most transcriptionally active SL1 complexes contain TAF I 41.
A mouse TAF I 41 orthologue in mSL1 (TIF-IB)
The discovery of a potential mouse orthologue in the sequence database prompted us to try and determine whether a functional TAF I 41 exists in mouse cells. There are no bands detectable at or around the calculated molecular weight of 37 kDa for the mouse homologue in TBP-affinity purified mouse SL1 (TIF-IB) (Rudloff et al, 1994) , although reduced silver staining and/or co-migration with, for example, mTAF I 48 could not be excluded. The human TAF I 41-peptides antibody did not detect a potential mouse homologue following immunoblotting of mouse nuclear extracts (data not shown). Nonetheless, human TAF I 41 antibody D immunoprecipitated TBP from mouse nuclear extracts ( Figure 3C , lane 4 compared to 2) and reduced Pol I transcription in these extracts ( Figure 3D , lane 2 compared to 1), suggesting that mouse TAF I 41 might be a component of transcriptionally active mSL1 (TIF-IB) complexes. SL1 is a major determinant in the species specificity of Pol I transcription (Heix and Grummt, 1995) . Overexpression of human TAF I 41 in mouse cells did not reprogramme these cells to transcribe a human rDNA promoter (data not shown).
siRNA-mediated downregulation of TAF I 41 expression in cells decreases Pol I transcription A positive role for TAF I 41 in Pol I transcription is suggested by the findings that TAF I 41 is a component of active SL1 complexes. To determine whether or not TAF I 41 is required for Pol I transcription in cells, we downregulated its expression using siRNAs. Human embryonic kidney 293 (HEK293) cells transfected with TAF I 41-siRNA showed reduced levels of TAF I 41 mRNA (data not shown) and protein (to less than 25%; Figure 4A , lanes 1-3 compared to lanes 4-6). Concomitant with downregulated TAF I 41 expression, a decreased level of 47S pre-rRNA was detected in these cells ( Figure 4B , lanes 1-3 compared to lanes 4-6, and bar graph). TAF I 41-siRNA also mediated downregulation of TAF I 41 expression ( Figure 4C ) and decreased pre-rRNA levels ( Figure 4D , lane 1) in SJSA cells, in contrast to the control siRNA ( Figure 4C and D, lane 4) . siRNA-mediated downregulation of the expression of SL1 subunit TAF I 48 or essential Pol I-associated factor RRN3 ( Figure 4C ) similarly reduced Pol I transcription ( Figure 4D , lanes 2 and 3, respectively). Consistent with these findings, nuclear extracts from TAF I 41-siRNA-treated cells supported a reduced level of Pol I transcription ( Figure 4E , lane 1 compared to 4) and an increased level of transcription was detectable in these extracts following addition of SL1 ( Figure 4E, lanes 2 and  3) . Taken together, these results suggest that siRNA-mediated downregulation of TAF I 41 expression in cells specifically impairs the function of SL1, implying a role for TAF I 41 in SL1 function.
Downregulation of TAF I 41 expression decreases the rDNA promoter occupancy of SL1 and Pol I in cells
The observed reductions in Pol I transcription in cells transfected with siRNAs for the TAF I 48 and TAF I 41 subunits of SL1 (Figure 4 ) support an in vivo role for SL1 in Pol I transcription of the rRNA genes. To provide further evidence for this and examine the role of SL1 and TAF I 41 in Pol I transcription in vivo, we downregulated TAF I 41 expression in cells and analysed the consequences for SL1 and Pol I occupancy at the rDNA repeat by ChIP. siRNA-mediated downregulation of TAF I 41 expression not only impaired SL1 function (Figure 4 ) but also drastically decreased the rDNA promoter occupancy of SL1 subunit TAF I 110 and Pol I subunit A135 ( Figure 5 ). SL1 can direct PIC formation in vitro (Smith et al, 1990 (Smith et al, , 1993 Schnapp and Grummt, 1991; Friedrich et al, 2005) , but a role for SL1 in this process in vivo had not been demonstrated. Our finding that the presence of Pol I at the rDNA promoter is dependent on the presence of SL1 provides evidence to suggest that SL1, including TAF I 41, is required for Pol I recruitment and, hence, PIC formation 1 and 2) or control (IgG, lanes 3 and 4), were analysed in a specific transcription assay with the human rDNA promoter, in the absence (lanes 1 and 3) or presence of added purified SL1 (Superose 6 fraction; 1 ml, lanes 2 and 4). Transcripts were analysed by S1 nuclease protection. (C) Human TAF I 41 antibodies immunoprecipitate mouse TBP from mouse 3T3 nuclear extract. Mouse 3T3 nuclear extract (25 ml) was incubated with hTAF I 41 antibody D (lanes 4 and 5) or control (IgG, lanes 2 and 3) overnight at 41C. Immunoprecipitated complex (IP) and 10% of the immunodepleted extract (ID) were immunoblotted with antibodies specific for TBP. Partially purified mouse SL1 (TIF-IB) (lane 1) was loaded as a marker. (D) Human TAF I 41 antibodies partially deplete Pol I transcription activity from mouse cell nuclear extract. In all, 15% of the extracts immunodepleted by hTAF I 41 antibody D (lane 2) or control (lane 1) antibodies were analysed in a specific transcription assay using the mouse rDNA promoter. Transcripts were analysed by S1 nuclease protection with a 5 0 -end labelled oligonucleotide complementary to the first 40 nt of the mouse pre-rRNA. Lane 3 contains the control transcription reaction with mouse nuclear extract (mNE).
in vivo. This is consistent with the observed dramatic decrease in Pol I A135 occupancy in transcribed regions of the rDNA repeat ( Figure 5 ). Figure 6C, lane 2) .
TAF I 41 interacts with UBF and might function as a coactivator in UBF-activated transcription
To analyse the functional significance of the UBF-TAF I 41 interaction, we tested the effect of TAF I 41 upon UBF-activated transcription in a reconstituted transcription reaction. Preinitiation complexes of SL1 and Pol I were assembled on an immobilized rDNA promoter template. Addition of recombinant TAF I 41 did not affect basal transcription from these templates ( Figure 6D , lane 9 compared to lanes 1 and 5). However, UBF-activated transcription was blocked by addition of recombinant TAF I 41 ( Figure 6D, lanes 10-12) . This squelching of UBF activation is likely to be specific, because GST alone ( Figure 6D , lanes 6-8) did not produce the effect. These data suggest a potential coactivator function for TAF I 41, but we do not yet have direct evidence for this. We are currently working to improve the efficiency and efficacy of reconstitution of Pol I transcription using SL1 assembled from its individual subunits TBP and TAF I s, 110, 63, 48 and 41, to enable further study of the individual roles of TAF I 41 and the other SL1 subunits.
In conclusion, we have demonstrated that TAF I 41 is a novel component of transcriptionally active SL1, important in Pol I transcription. Interestingly, the introns of the TAF I 41 gene (MGC5306) encode six H/ACA box snoRNAs and two C/D box snoRNAs (Kiss et al, 2004) , providing a link between transcription of the 47S pre-rRNA by Pol I and its processing and modification to produce the 18S, 5.8S and 28S rRNAs. We have observed a correlation between TAF I 41 expression levels and Pol I transcription activity in cells. Furthermore, our data implicate the SL1 complex, including TAF I 41, in recruitment of the Pol I complex to the rDNA promoter in vivo, perhaps through an interaction with RRN3/TIF-IA. We speculate that the TAF I 41 subunit of SL1 might also be required to upregulate Pol I transcription for sustained hyperproliferation of cells, particularly given the observed overexpression of TAF I 41 (MGC5306) in certain tumours ( (Wang et al, 2004) ; Pathak and Zomerdijk, unpublished results). The importance of TAF I 41 with respect to cell fate is also suggested by the -3) , or scrambled (control; lanes 4-6) were analysed for specific transcription activity in the absence (lanes 1 and 4) or presence of purified SL1 (Superose 6 fraction; 0.5 ml, lanes 2 and 5, or 1 ml, lanes 3 and 6).
finding that decreased expression of TAF I 41 activates the p53 response pathway (Pathak and Zomerdijk, unpublished results), induces apoptosis and reduces cell proliferation (Wang et al, 2004 ) most likely as a consequence of the downregulation of Pol I transcription.
Materials and methods
TAF I 41 antibodies TAF 1 41 peptides (MDKSGIDSLDH; ENEKNAPWRKIL; KAKNTGQ RGLKM), coupled to KLH, were used to generate rabbit polyclonal antibodies. This antibody is referred to as TAF I 41-peptides antibody and is used throughout this study primarily for probing immunoblots. The characterization of the TAF I 41-peptides antibody specificity is described (Supplementary Figure S2B and C) . Human TAF I 41 protein D (amino acids 98-204) was cloned in pGEX-4T vector and expressed in Escherichia coli BL21(DE3). GST-TAF I 41 (98-204) protein was affinity purified on glutathioneSepharose and after thrombin cleavage to release the TAF I 41 protein portion from GST, purified TAF I 41 protein was used to generate polyclonal sheep antibodies (Scottish National Blood Transfusion Service), which were affinity purified on HiTRAP NHS-activated HP coupled to purified hTAF I 41 protein D according to the manufacturer's instructions (Amersham Biosciences). This antibody was used in the immunoprecipitation and depletion experiments of Figure 3 .
Pol I transcription machinery components
Human SL1 was purified from HeLa cell nuclear extracts for analytical purposes as described in Figure 1A and B (and based in part on protocols described by Friedrich et al, 2005) . For preparative scale purification, we purified SL1 through the following columns: Heparin Agarose, SP-Sepharose, POROS-Heparin, Mono S and Superose 6, as detailed previously (Miller et al, 2001; Friedrich et al, 2005) ; this purified SL1 is referred to as Superose 6 fraction SL1. UBF and Pol I were purified as described previously (Miller et al, 2001; . Hela cell nuclei were purchased from the National Cell Culture Center (Minneapolis, MN, USA).
Immunoblotting and immunoprecipitation
Immunoblotting and immunoprecipitations used antibodies for human TAF I 41 (TAF I 41-peptides antibody, used in Westerns and IPs or TAFI41-antibody D, used in IPs; see above), TAF I 110, TAF I 63, TAF I 48, RRN3, TBP Zomerdijk et al, 1994; Heix et al, 1997; Miller et al, 2001) , GAPDH (clone 6C5, Research Diagnostics Inc.), Flag (Sigma) and GFP (Roche). For immunoprecipitation of Flag-or EGFP-tagged proteins, HeLa cells were S-radiolabelled TAF I 41 was incubated with membrane-bound, then denatured and renatured UBF protein (Far-WB; lane 2). Binding was analysed by autoradiography. In control lane 1, denatured-renatured UBF was detected by UBF-specific antibodies following Western blotting (WB). (D) TAF I 41 squelches UBF-activated but not basal SL1-directed Pol I transcription. Preinitiation complexes (PICs) of SL1 (Superose 6 fraction) and Pol I were assembled on an immobilized human rDNA promoter template (IT-rDNA, Fr4; Panov et al, 2001) for 30 min on ice. The PICs were washed in TM10/0.075 M KCl, then GST-TAF I 41 (50 ng) was added concomitantly with 0, 1, 10 and 20 ng of UBF (lanes 9, 10, 11 and 12, respectively) and NTPs and transcription was analysed by S1 nuclease protection. In the control samples, in place of GST-TAF I 41, no protein (lanes 1-4) or GST (50 ng; lanes 5-8) was used.
transfected (Effectene, Qiagen) with pcDNA-Flag-TAF I 41, pcDNAFlag-TAF I 63 (Flag peptide coding sequence and full-length cDNA of human TAF I 41 or TAF I 63 subcloned into pcDNA3.2/V5-DEST vector, Invitrogen) or pEGFP-TAF I 41, pEGFP-RRN3 expression vectors (full-length cDNA of human TAF I 41 or RRN3 subcloned into pEGFP, Invitrogen), and 'empty' expression vectors were used as controls in these transfections. Precleared nuclear extract (0.4 mg) from these transfected cells was incubated with Flagspecific or GFP-specific antibody beads in TM10/0.2 M KCl (50 mM Tris-HCl pH 7.9, 12.5 mM MgCl 2 , 1 mM EDTA, 10% glycerol, 1 mM sodium-metabisulphite, 1 mM DTT, 0.015% NP40) for 2 h at 41C, beads were washed and Flag precipitants were eluted by Flag peptide as described (Panova et al, 2006) . For immunoprecipitation of endogenous proteins, 0.4 mg of precleared nuclear extract was incubated with antibody on Protein A Dynabeads in TM10/0.2 M KCl overnight at 41C; beads were washed extensively in TM10/0.2.
In vitro transcription
In vitro Pol I transcription assays with human rDNA promoter (Fr 4, À193 to þ 239) or mouse rDNA promoter (À182 to þ 23) fragments were performed as described (Miller et al, 2001; Panov et al, 2001) . The SL1 used for add-back into in vitro transcription reactions (Figures 3 and 4) was purified over the following columns: Heparin Agarose, SP-Sepharose, POROS-Heparin, Mono S and Superose 6, as detailed previously (Miller et al, 2001; Friedrich et al, 2005) . This SL1 (Superose 6 fraction) is free of UBF and Pol I.
siRNA-mediated repression of hTAF I 41, TAF I 48 and RRN3 expression HeLa, HEK293 or human astrocytoma SJSA cells (cultured in DMEM with 10% FCS) were transfected (Oligofectamine, Invitrogen) with synthetic siRNA (100 nM; Dharmacon) for hTAF I 41 (target sequence 5 0 -AAGTGATTCATCAAGTGACTC), TAF I 48 (5 0 -AAGAGGTACTCACC AATTATG), RRN3 (5 0 -AAATATGCGTGCATTAGAGAA) or Control (5 0 -AACAGTCGCGTTTGCGACTGG). After 48 h, nuclear extracts were prepared, and analysed by immunoblotting (with GAPDH serving as a reference) and/or used in in vitro transcription reactions; total RNA was isolated from the siRNA-treated cells to assess pre-rRNA levels by S1 nuclease protection as described (James and Zomerdijk, 2004) . Messenger RNA levels were analysed by quantitative real-time PCR as outlined. Three siRNAs for TAF I 41 were tested; the TAF I 41-siRNA that caused the most effective repression of TAF I 41 gene expression in cells is used throughout this study. mRNA extraction and quantification by real-time PCR Total RNA from siRNA-treated cell cultures was isolated using the RNeasy mini-kit (Qiagen), including an on-column DNase I treatment step. RNA (200 ng) was subsequently reverse-transcribed into cDNA with Superscript II (Invitrogen) using random hexamers. Real-time PCR (Taqman, Applied Biosystems) was carried out with an ABI Prism 7900 sequence detector using the following protocol: 501C for 2 min, 951C for 10 min and 40 cycles of 951C for 15 s and 601C for 1 min. Primers used were: for TAF I 48: forward (f) primer 5 0 -TGCTCAGTGGTGCAGGAATG and reverse (r) 5 0 -CCTCCAATGGC CACAGTTTC, and Taqman probe: 6-FAM-ATTTTCCTTGGCTT CAAACATACG-TAMRA; for RRN3: (f) primer 5 0 -AGAACCAGCTGTT AGATCCAGACATA, and (r) 5 0 -TCAAGTACATGATAGAAGAACGGAA TTC and Taqman probe 6-FAM-AGGATGACCAGATCATCAACTGGCT-TAMRA.
TAF I 41 mRNA was first reverse transcribed and then the cDNA was amplified using SYBR Green PCR master mix (Applied Biosystems) and specific primers in an ABI Prism 7900 system (Applied Biosystems). The primers used were: (f) 5 0 -CATGTGA CATCTGATGCTGTGGAAC and (r) 5 0 -CGTGAACACTTTCAGGTGTAC GAAC. PCR conditions used were: 501C for 2 min, 951C for 10 min, and 50 cycles of 951C for 15 s and 601C for 1 min. Primers and Taqman probe for b-actin were purchased from Applied Biosystems. Relative quantification of gene expression was performed using the comparative threshold (C T ) method. Changes in mRNA expression levels were calculated following normalization to b-actin mRNA levels.
In vitro binding assays
Interactions of TAF I 41 with UBF or luciferase were analysed using recombinant baculovirus-Sf9 cell-expressed His-TAF I 41 (purified on Ni-NTA beads according to the manufacturer's instructions (Qiagen)) and 35 S-labeled in vitro translated (TNT-coupled reticulocyte lysate system (Promega)) UBF or luciferase in in vitro binding assays.
In an alternative protein-protein binding assay, GST or GST-TAF I 41 (expressed in E. coli and purified on glutathione-Sepharose according to the manufacturer (Amersham Biosciences)) was mixed with baculovirus-Sf9 cell-expressed and purified UBF .
In vitro binding assays were performed in 75 mM KCl in TM10 buffer plus 0.015% NP-40 for 30 min at 01C. After binding, beads were extensively washed with 0.1 M KCl in TM10 and bound protein were analysed by autoradiography.
Far-Western analyses involved SDS-PAGE of recombinant purified UBF, transfer to membrane, denaturation and renaturation of membrane-bound UBF, incubation of the membrane with 35 Sradiolabelled in vitro translated TAF I 41 (using subclone pcDNA3.2/ V5-DEST(Invitrogen)-TAF I 41) and analysis of bound proteins by autoradiography as described (Miller et al, 2001 ).
Nucleolar chromatin immunoprecipitations
Nucleolar chromatin immunoprecipitations (ChIPs) were performed essentially as described by O'Sullivan et al (2002) with some modifications. HeLa or HEK293 cells were cultured to approximately 70% confluency, and the medium was refreshed 1 h before crosslinking. Crosslinking was performed for 10 min at 371C by the addition of freshly made paraformaldehyde to a final concentration of 0.25-1%. Cells were collected into cold PBS supplemented with 1 mM AEBSF, pelleted, washed with PBS, and resuspended in high-magnesium buffer (10 mM HEPES pH 7.5, 0.88 M sucrose, 12 mM MgCl 2 , 1 mM DTT, Complete protease inhibitors (Roche)). Nucleoli were released by sonication, pelleted, resuspended in low-magnesium buffer (10 mM HEPES pH 7.5, 0.88 M sucrose, 1 mM MgCl 2 , 1 mM DTT, Complete protease inhibitors (Roche)), further sonicated and pelleted. The nucleoli were then resuspended in 1% SDS, 10 mM EDTA (pH 8), 50 mM Tris-HCl (pH 8), Complete protease inhibitor, and further SDS was added to a final concentration of 2%. After the lysis of the nucleoli (371C for 15 min), the solution was diluted five-fold with TE buffer containing Complete protease inhibitors, sonicated, the resulting sheared nucleolar chromatin was centrifuged (15 000 g for 1 min), and the supernatant was used in nucleolar ChIP assays after quantification of input total DNA and determining the size of resulting sheared nucleolar DNA (fragments in the 250-300 bp size range).
Nucleolar ChIPs were performed using TBP-antibody (mouse monoclonal 3G3, kind gift from Dr L Tora), TAF I 41-peptides rabbit polyclonal antibody, TAF I 110 rabbit polyclonal antibody , A135 (Pol I second largest subunit) goat polyclonal antibody (Santa Cruz Biotech, Inc.) or the appropriate control IgG (Sigma) or preimmune serum immobilized on Protein G paramagnetic beads (Dynal). QPCR analysis was performed using SYBR Green PCR Master Mix and ABI7000 (both Applied Biosystems). For the ChIP analysis in Figure 1 
Supplementary data
Supplementary data are available at The EMBO Journal Online (http://www.embojournal.org).
